Advertisement

Topics

Sandoz resubmits Neulasta biosimilar application to FDA

13:30 EDT 12 Apr 2019 | Drug Store News

pharmacy/sandoz-resubmits-neulasta-biosimilar-application-to-fda/">

Sandoz's biosimilar of Neulasta, pegfilgrastim, is a long-acting version of filgrastim for cancer patients.

Read More

Original Article: Sandoz resubmits Neulasta biosimilar application to FDA

NEXT ARTICLE

More From BioPortfolio on "Sandoz resubmits Neulasta biosimilar application to FDA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...